ProAir RespiClick albuterol sulfate regulatory update

FDA accepted for review an sNDA from Teva for ProAir RespiClick albuterol sulfate inhalation powder to treat or prevent bronchospasms in patients ages 4-11 with reversible obstructive airway disease a...